STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

NCT00006343 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: recombinant interferon alfa
DRUG: cytarabine
DRUG: imatinib mesylate

Sponsor

Novartis

Collaborators

[object Object]